Nestlé will acquire the maker of a peanut allergy drug for $2.6 billion
Nestlé is buying the maker of a peanut allergy drug for $2.6 billion. Aimmune (AIMT) is a California-based biotechnology firm that received USDA approval for Palforzia, a drug designed to help children build up their immune response to peanuts, CNN reports. Nestlé, the world’s largest food and beverage company, has now made multiple investments into researching and developing food allergy-related products via its Nestlé Health Sciences division.
